Skip to main content

Advertisement

Fig. 5 | Journal of Translational Medicine

Fig. 5

From: Pharmacologic rationale for the NK1R antagonist, aprepitant as adjunctive therapy in HIV

Fig. 5

SP dependent up regulation of cytokine and chemokine production by human PBMC* is inhibited by aprepitant. *Freshly isolated PBMC from normal donors were incubated for 24 h with SP and/or Aprepitant (10 µM each) as indicated. Control cultures were either left untreated of incubated with DMSO (vehicle for aprepitant). Pro-inflammatory markers were measured in supernatants using MILLIPORE Human Cytokine/Chemokine Magnetic Bead Panel. Results are presented as mean ± SD for three independent experiments. *Statistically significant difference from control (p < 0.05)

Back to article page